These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21206997)

  • 1. [Metabolic disorders under antipsychotic treatment].
    Steffenhagen N; Rummel-Kluge C; Himmerich H
    Nervenarzt; 2012 Mar; 83(3):337-44. PubMed ID: 21206997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics.
    Correll CU; Frederickson AM; Kane JM; Manu P
    Bipolar Disord; 2008 Nov; 10(7):788-97. PubMed ID: 19032710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs.
    Falissard B; Mauri M; Shaw K; Wetterling T; Doble A; Giudicelli A; De Hert M
    Int Clin Psychopharmacol; 2011 Nov; 26(6):291-302. PubMed ID: 21876442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial.
    Fleischhacker WW; Siu CO; Bodén R; Pappadopulos E; Karayal ON; Kahn RS;
    Int J Neuropsychopharmacol; 2013 Jun; 16(5):987-95. PubMed ID: 23253821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents.
    McIntyre RS; Jerrell JM
    Arch Pediatr Adolesc Med; 2008 Oct; 162(10):929-35. PubMed ID: 18838645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Schizophrenia and comorbid metabolic disorders.
    Henderson DC
    J Clin Psychiatry; 2005; 66 Suppl 6():11-20. PubMed ID: 16107179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of monitoring and management guidelines for second-generation antipsychotics.
    Sernyak MJ
    J Clin Psychiatry; 2007; 68 Suppl 4():14-8. PubMed ID: 17539695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilization.
    Masand PS; Culpepper L; Henderson D; Lee S; Littrell K; Newcomer JW; Rasgon N
    CNS Spectr; 2005 Oct; 10(10):suppl14 1-15. PubMed ID: 16404802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study.
    Bai YM; Chen TT; Yang WS; Chi YC; Lin CC; Liou YJ; Wang YC; Su TP; Chou P; Chen JY
    Schizophr Res; 2009 Jun; 111(1-3):1-8. PubMed ID: 19409756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients.
    Mackin P; Bishop DR; Watkinson HM
    BMC Psychiatry; 2007 Jun; 7():28. PubMed ID: 17592636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors in second-generation antipsychotic switching patterns in a national sample of older veterans with schizophrenia.
    Dassori AM; Copeland LA; Zeber JE; Miller AL
    Psychiatr Serv; 2011 Jan; 62(1):47-53. PubMed ID: 21209299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse effects of atypical antipsychotics : differential risk and clinical implications.
    Haddad PM; Sharma SG
    CNS Drugs; 2007; 21(11):911-36. PubMed ID: 17927296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
    Newcomer JW
    CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review.
    De Hert M; Schreurs V; Sweers K; Van Eyck D; Hanssens L; Sinko S; Wampers M; Scheen A; Peuskens J; van Winkel R
    Schizophr Res; 2008 Apr; 101(1-3):295-303. PubMed ID: 18299188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Metabolic risk during antipsychotic treatment in patients with schizophrenia].
    Rzewuska M
    Psychiatr Pol; 2007; 41(4):457-72. PubMed ID: 18046977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term metabolic and cardiovascular effects of antipsychotic drugs. A meta-analysis of randomized controlled trials.
    Rotella F; Cassioli E; Calderani E; Lazzeretti L; Ragghianti B; Ricca V; Mannucci E
    Eur Neuropsychopharmacol; 2020 Mar; 32():56-65. PubMed ID: 31917068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Brazilian Consensus on second-generation antipsychotics and metabolic disorders].
    Elkis H; Gama C; Suplicy H; Tambascia M; Bressan R; Lyra R; Cavalcante S; Minicucci W
    Braz J Psychiatry; 2008 Mar; 30(1):77-85. PubMed ID: 18373022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.